ArticleTheranostics2019

ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.

Jie Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.